


Efavirenz versus Protease Inhibitors in Patients with HIV: A Systematic Review and Meta-Analysis

Sabina O. Nduaguba^{1*}, Chinyere Okoh², Jamie C. Barner², Kentya H. Ford³, James P. Wilson², Kenneth A. Lawson², James N. Barnes⁴, and Tasha Beretvas⁵

¹Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL; ²Health Outcomes Division, The University of Texas at Austin College of Pharmacy, Austin, TX; ³Department of Health and Kinesiology, Prairie View A&M University, College Station, TX; ⁴Feik School of Pharmacy, University of the Incarnate Word, San Antonio, TX; ⁵Department of Educational Psychology, The University of Texas at Austin, TX. USAz

Supplementary Table 1. Meta-analysis of the Efficacy of Efavirenz versus Protease Inhibitors on Virological Suppression – Sensitivity Analysis*



*Efavirenz-PI pairs with either zidovudine/didanosine or didanosine/stavudine NRTI backbones excluded
^bPI; NRTI backbone; follow-up (weeks); viral load detection limit
3TC: lamivudine; ABC: abacavir; ATV: atazanavir; d4T: stavudine; ddI: didanosine; FPV: fosamprenavir; FTC: emtricitabine; IDV: indinavir; LPV: lopinavir; NFV: nefinavir; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; r: ritonavir; TDF: tenofovir; ZDV: zidovudine.